Sarcoma & Merkel cell carcinoma Medical oncologist l Immunotherapy expert l Memorial Sloan Kettering Cancer Center l Tweets are my own
New York, NY
Joined May 2015
- Tweets548
- Following509
- Followers1.6K
- Likes3.2K
Sandra P D'Angelo, MD retweeted
Past Conquer Cancer grant recipient Dr. Mark Dickson’s 15+ year journey in sarcoma research shows that persistence pays off. His early-career funding paved the way for Phase 3 clinical trials that are redefining care for rare sarcomas. Read his researcher spotlight: bit.ly/4bb08Hp
Sandra P D'Angelo, MD retweeted
A powerhouse group representing MSK at the #ASCO26 plenary. 💙
A few butterflies🦋 before the #ASCO26 Plenary. #2025Plenary podium was unforgettable , but this seat is definitely more relaxed. Emotions are high for the PDAC and sarcoma presentations. If we can change practice in these recalcitrant diseases, anything is possible! 💜💜💜
Sandra P D'Angelo, MD retweeted
Liposarcoma in the holy grail of oncology - the Plenary Session at the ASCO Annual Meeting 2026. Congratulations to Mark A. Dickson and all SARC041 investigators!
Sandra P D'Angelo, MD retweeted
Sandra P. D’Angelo, Alexander N. Shoustari, and Mark Yarchoan will discuss "Harnessing Immunotherapy for Rare Cancers" in a plenary session at the AACR Conference on Rare Cancers (July 18-20, Vancouver).
brnw.ch/21x2wVT
#AACRrarecancers26 @sandrapdangelo @MarkYarchoan
Sandra P D'Angelo, MD retweeted
Don’t Just Attend ASCO — Be at the Right Sessions
🌍 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐨𝐢𝐜𝐞𝐬 𝐢𝐧 𝐒𝐚𝐫𝐜𝐨𝐦𝐚 — 𝐋𝐢𝐯𝐞 𝐚𝐭 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔
OncoDaily Grand Rounds: Sarcoma Edition
📅 May 29
🕒 – pm
📍 Hilton Chicago
@sandrapdangelo • @herbloong • @BrotoJavier • @RobinL_Jones
Featuring leading experts shaping the field today.
🤝Foundational partner: @EliLillyandCo
🥉 Bronze Sponsor: @USWorldMeds
🔗Register: docs.google.com/forms/d/e/1F…
🔗 oncodaily.com/grand-rounds-a…
#OncoDailyGrandRoundsSarcoma
1/
Proud to share our phase 2 study of palbociclib + retifanlimab in advanced dedifferentiated liposarcoma #DDLPS. This work builds on MSK’s longstanding effort to improve outcomes in DDLPS — from CDK4/6 inhibitor monotherapy, to immunotherapy, to rational combinations.
New #JITC article: "Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma" jitc.bmj.com/content/14/5/e0…
@sandrapdangelo @ESeffar @MSKCancerCenter @WTapMD
This study is part of a broader MSK DDLPS legacy — from Dr. Mark Dickson’s foundational palbociclib and abemaciclib work (@ASCO 2026 plenary), to immunotherapy studies, to current rational combinations including palbociclib + MEK inhibition led by Dr. Babatunde and Dr. Tap.
These data support continued biomarker driven development of CDK4/6 based combinations in DDLPS to improve patient selection, deepen responses, and building more effective therapeutic strategies for this rare sarcoma. #Sarcoma #Liposarcoma #Immunotherapy @MSK_DeptOfMed @WTapMD
Sandra P D'Angelo, MD retweeted
Moving Immunotherapy Toward Biomarker-Driven Precision Care - Sandra D'Angelo (@sandrapdangelo)
oncodaily.com/voices/sandra-…
#OncoDaily #Oncology #Cancer #Health #Medicine #Immunotherapy #MedX
This study helps move sarcoma immunotherapy toward biomarker-driven precision care. By integrating circulating immune profiles, tumor microenvironment features, and digital pathology, we identify signals that may help predict who is most likely to benefit from ICB.
Now online: Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma doi.org/10.1158/1078-0432.CC…
Sandra P D'Angelo, MD retweeted
The #statusquo of #immunotherapy was challenged at @myesmo #ESMORareCancer26 during a dedicated session. Kicked off by Prof. #AntoineItaliano outlining 'established' and 'emerging' #biomarkers and #immune profiling, together with on-going projects in this field
Palbociclib → retifanlimab in DDLPS shows immune‐related toxicity with sequential dosing, prompting change to concurrent dosing. Prelim single-cell + flow analyses reveal cell-cycle suppression, senescence induction and T/B-cell infiltration. Analysis of final cohort pending.
Recently published:
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated #Liposarcoma, by Evan Rosenbaum et al. doi.org/10.1158/2767-9764.CR…
@sandrapdangelo @MSKCancerCenter @WeillCornell #Sarcoma #OpenAccess
Sandra P D'Angelo, MD retweeted
#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes.
Read more #ESMODailyReporter 📌 ow.ly/EnY550XieWa
@sandrapdangelo
